Abstract
During the past 10 years, substantial progress has been made in the discovery and development of small molecule glutamate carboxypeptidase II (GCP II) inhibitors. These inhibitors have provided the necessary tools to investigate the physiological role of GCP II as well as the potential therapeutic benefits of its inhibition in neurological disorders of glutamatergic dysregulation. This review article details key GCP II inhibitors discovered in the last decade and important findings from preclinical and clinical studies.
Original language | English (US) |
---|---|
Pages (from-to) | 767-776 |
Number of pages | 10 |
Journal | Drug Discovery Today |
Volume | 12 |
Issue number | 17-18 |
DOIs | |
State | Published - Sep 2007 |
Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery